Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Randomized, Double-blind, Placebo-controlled, Group-comparison, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administration of Different Doses of Vardenafil (2 Dose Strengths) and BAY60-4552 (4 Dose Strengths) Given Once-daily (od) Over 14 Days in Patients With Erectile Dysfunction (ED).

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in this
multiple dose escalation study. In three treatments groups different dosages of BAY 60-4552
and vardenafil will be given with patients with erectile dysfunction.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003991
  •   2012/11/22
  •   2010/04/14
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2009-015894-11 
  •   NCT01110590  (
  •   14612  (Bayer)
  •   2009-015894-11 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Erectile Dysfunction
  •   N48.4 -  Impotence of organic origin
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: BAY60-4552 + Vardenafil
  •   Drug: BAY60-4552 + Vardenafil
  •   Drug: BAY60-4552 + Vardenafil
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo
  •   [---]*
  •   Parallel
  •   I
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Adverse Event reporting; time frame: up to 6 weeks

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Plasma concentration of study drugs; Pharmacokinetic parameters: AUC, Cmax, AUC/D, Cmax;norm, Cmax/D, t1/2, tmax; time frame: Day 0, 6, 13
- Plasma concentration of cyclic guanosine monophosphate (cGMP); time frame: Day 0, 6, 13

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2010/01/31
  •   37
  •   [---]*
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Male
  •   18   Years
  •   70   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- The informed consent must be signed before any study specific tests or procedures are

- Male patients with a history of erectile dysfunction (ED) for at least 6 months,
defined as "the inability to achieve and maintain an erection of the penis sufficient
to complete satisfactory sexual intercourse" by the NIH consensus report 1993. The
diagnosis of 'Erectile dysfunction' has to be confirmed by a physician

- Age: 18 to 70 years (inclusive) at the first screening examination

- Ethnicity: White

- Body mass index (BMI): equal to or above 18 and below 32 kg / m²

- Confirmation of the patient's health insurance coverage prior to the first screening
examination / visit

- Ability to understand and follow study-related instructions

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Incompletely cured pre-existing diseases for which it can be assumed that the
absorption, distribution, metabolism, elimination and effects of the study drugs will
not be normal

- Known hypersensitivity to the study drugs (active substances or excipients of the

- Known severe allergies, non-allergic drug reactions, or multiple drug allergies

- Any underlying cardiovascular condition, including unstable angina pectoris that
would preclude sexual activity according to the NIH consensus report 1993

- History of myocardial infarction, stroke or life-threatening arrhythmia within 6
months prior to screening

- Bleeding disorder

- History of prostatectomy because of prostate cancer, including nerve-sparing
techniques. Clarification: Any surgical procedures for the treatment of Benign
Prostate Hypertrophy (BPH) are permitted, with the exception of cryosurgery,
cryotherapy or cryoablation

- Hereditary degenerative retinal disorders such as retinitis pigmentosa

- History of loss of vision because of NAION (Bayer Study 12912), temporary or
permanent loss of vision, including unilateral loss of vision

- History of uni- or bilateral hearing loss

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Bayer
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Bayer
    • Bayer Study Director 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Bayer
    • Bayer Study Director 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   2010/05/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   5
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.